Garrett M Brodeur

Summary

Affiliation: The Children's Hospital of Philadelphia
Country: USA

Publications

  1. pmc Trk receptor expression and inhibition in neuroblastomas
    Garrett M Brodeur
    Division of Oncology, The Children s Hospital of Philadelphia, University of Pennsylvania School of Medicine, Philadelphia, PA 19104 4318, USA
    Clin Cancer Res 15:3244-50. 2009
  2. pmc CHD5, a tumor suppressor gene deleted from 1p36.31 in neuroblastomas
    Tomoyuki Fujita
    Division of Oncology, The Children s Hospital of Philadelphia, Philadelphia, PA 19104 4318, USA
    J Natl Cancer Inst 100:940-9. 2008
  3. pmc Clinical significance of NTRK family gene expression in neuroblastomas
    Jennifer E Light
    Division of Oncology, The Children s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA
    Pediatr Blood Cancer 59:226-32. 2012
  4. pmc Mechanisms of CHD5 Inactivation in neuroblastomas
    Hiroshi Koyama
    Division of Oncology, The Children s Hospital of Philadelphia, Philadelphia, PA, USA
    Clin Cancer Res 18:1588-97. 2012
  5. pmc AZ64 inhibits TrkB and enhances the efficacy of chemotherapy and local radiation in neuroblastoma xenografts
    Radhika Iyer
    Division of Oncology, Children s Hospital of Philadelphia, PA 19104 4302, USA
    Cancer Chemother Pharmacol 70:477-86. 2012
  6. pmc The effect of P75 on Trk receptors in neuroblastomas
    Ruth Ho
    Division of Oncology, The Children s Hospital of Philadelphia, PA 19104, United States
    Cancer Lett 305:76-85. 2011
  7. ncbi Definition and characterization of a region of 1p36.3 consistently deleted in neuroblastoma
    Peter S White
    Division of Oncology, The Children s Hospital of Philadelphia, 3516 Civic Center Blvd, Philadelphia, PA 19104, USA
    Oncogene 24:2684-94. 2005
  8. ncbi Resistance to chemotherapy mediated by TrkB in neuroblastomas
    Ruth Ho
    Division of Oncology, The Children s Hospital of Philadelphia and the University of Pennsylvania, Philadelphia, Pennsylvania 19104 4318, USA
    Cancer Res 62:6462-6. 2002
  9. pmc Identification of ALK as a major familial neuroblastoma predisposition gene
    Yael P Mosse
    Division of Oncology and Center for Childhood Cancer Research, Children s Hospital of Philadelphia, Department of Pediatrics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    Nature 455:930-5. 2008
  10. pmc Lestaurtinib enhances the antitumor efficacy of chemotherapy in murine xenograft models of neuroblastoma
    Radhika Iyer
    Division of Oncology and Biostatistics and Data Management Core, Children s Hospital of Philadelphia, Philadelphia, Pennsylvania 19104, USA
    Clin Cancer Res 16:1478-85. 2010

Collaborators

Detail Information

Publications34

  1. pmc Trk receptor expression and inhibition in neuroblastomas
    Garrett M Brodeur
    Division of Oncology, The Children s Hospital of Philadelphia, University of Pennsylvania School of Medicine, Philadelphia, PA 19104 4318, USA
    Clin Cancer Res 15:3244-50. 2009
    ..Finally we address the progress that has been made in developing targeted therapy with Trk-selective inhibitors to treat neuroblastomas and other tumors with activated Trk expression...
  2. pmc CHD5, a tumor suppressor gene deleted from 1p36.31 in neuroblastomas
    Tomoyuki Fujita
    Division of Oncology, The Children s Hospital of Philadelphia, Philadelphia, PA 19104 4318, USA
    J Natl Cancer Inst 100:940-9. 2008
    ..31 that encodes 23 genes. Based on mutation analysis, expression pattern, and putative function, we identified CHD5 as the best tumor suppressor gene candidate...
  3. pmc Clinical significance of NTRK family gene expression in neuroblastomas
    Jennifer E Light
    Division of Oncology, The Children s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA
    Pediatr Blood Cancer 59:226-32. 2012
    ..We determined the significance of NTRK family gene expression in a large, representative set of primary NBs...
  4. pmc Mechanisms of CHD5 Inactivation in neuroblastomas
    Hiroshi Koyama
    Division of Oncology, The Children s Hospital of Philadelphia, Philadelphia, PA, USA
    Clin Cancer Res 18:1588-97. 2012
    ..31. Low or absent CHD5 expression is associated with a 1p36 deletion and an unfavorable outcome, but the mechanisms of CHD5 inactivation in NBs are unknown...
  5. pmc AZ64 inhibits TrkB and enhances the efficacy of chemotherapy and local radiation in neuroblastoma xenografts
    Radhika Iyer
    Division of Oncology, Children s Hospital of Philadelphia, PA 19104 4302, USA
    Cancer Chemother Pharmacol 70:477-86. 2012
    ..More importantly, it can significantly enhance the efficacy of conventional chemotherapy as well as local RT, presumably by inhibition of the NTRK2/BDNF autocrine survival pathway...
  6. pmc The effect of P75 on Trk receptors in neuroblastomas
    Ruth Ho
    Division of Oncology, The Children s Hospital of Philadelphia, PA 19104, United States
    Cancer Lett 305:76-85. 2011
    ..It also enhances ligand-induced differentiation in TrkA/p75 but not TrkB/p75 cells...
  7. ncbi Definition and characterization of a region of 1p36.3 consistently deleted in neuroblastoma
    Peter S White
    Division of Oncology, The Children s Hospital of Philadelphia, 3516 Civic Center Blvd, Philadelphia, PA 19104, USA
    Oncogene 24:2684-94. 2005
    ..Together, these results suggest that one or more genes involved in neuroblastoma tumorigenesis or tumor progression are likely contained within this region...
  8. ncbi Resistance to chemotherapy mediated by TrkB in neuroblastomas
    Ruth Ho
    Division of Oncology, The Children s Hospital of Philadelphia and the University of Pennsylvania, Philadelphia, Pennsylvania 19104 4318, USA
    Cancer Res 62:6462-6. 2002
    ..Activation of PI3K/AKT survival pathway may contribute to the increased drug resistance in TrkB-expressing neuroblastomas...
  9. pmc Identification of ALK as a major familial neuroblastoma predisposition gene
    Yael P Mosse
    Division of Oncology and Center for Childhood Cancer Research, Children s Hospital of Philadelphia, Department of Pediatrics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    Nature 455:930-5. 2008
    ....
  10. pmc Lestaurtinib enhances the antitumor efficacy of chemotherapy in murine xenograft models of neuroblastoma
    Radhika Iyer
    Division of Oncology and Biostatistics and Data Management Core, Children s Hospital of Philadelphia, Philadelphia, Pennsylvania 19104, USA
    Clin Cancer Res 16:1478-85. 2010
    ..We wanted to determine if the Trk-selective inhibitor lestaurtinib had therapeutic efficacy in a preclinical neuroblastoma model...
  11. pmc Role of microRNAs in epigenetic silencing of the CHD5 tumor suppressor gene in neuroblastomas
    Koumudi Naraparaju
    Division of Oncology and Hematology, The Children s Hospital of Philadelphia, University of Pennsylvania, Philadelphia, PA, USA
    Oncotarget 7:15977-85. 2016
    ..Interestingly, MYCN upregulates several of the candidates we identified: miR-17, -93, -106b & -20b. This suggests that miRNAs driven by MYCN and other genes represent a potential epigenetic mechanism to regulate CHD5 expression. ..
  12. ncbi Chromosome 1p and 11q deletions and outcome in neuroblastoma
    Edward F Attiyeh
    Children s Hospital of Philadelphia, University of Pennsylvania School of Medicine, PA 19104 4318, USA
    N Engl J Med 353:2243-53. 2005
    ..Neuroblastoma is a childhood cancer with considerable morbidity and mortality. Tumor-derived biomarkers may improve risk stratification...
  13. ncbi Neuroblastoma: biological insights into a clinical enigma
    Garrett M Brodeur
    Division of Oncology, The Children s Hospital of Philadelphia and the University of Pennsylvania, Philadelphia, Pennsylvania 19104 4318, USA
    Nat Rev Cancer 3:203-16. 2003
    ..Future therapies will focus increasingly on the genes and biological pathways that contribute to malignant transformation or progression...
  14. pmc A functional screen identifies miR-34a as a candidate neuroblastoma tumor suppressor gene
    Kristina A Cole
    Division of Oncology, Children s Hospital of Philadelphia, Abramson Pediatric Research Center 902A, 3615 Civic Center Boulevard, Philadelphia, PA 19104 4318, USA
    Mol Cancer Res 6:735-42. 2008
    ..BCL2 and MYCN were identified as miR-34a targets and likely mediators of the tumor suppressor phenotypic effect. These data support miR-34a as a tumor suppressor gene in human neuroblastoma...
  15. pmc Retinoic acid-induced CHD5 upregulation and neuronal differentiation of neuroblastoma
    Mayumi Higashi
    Division of Oncology, Children s Hospital of Philadelphia, and the Department of Pediatrics, University of Pennsylvania School of Medicine, CTRB Rm 3018, 3501 Civic Center Blvd, Philadelphia, PA, 19104 4302, USA
    Mol Cancer 14:150. 2015
    ..High CHD5 expression is associated with a favorable prognosis, but deletion or low expression is frequent in high-risk tumors. We explored the role of CHD5 expression in the neuronal differentiation of NB cell lines...
  16. pmc Nanoparticle delivery of an SN38 conjugate is more effective than irinotecan in a mouse model of neuroblastoma
    Radhika Iyer
    Division of Oncology, The Children s Hospital of Philadelphia, 3400 Civic Center Blvd, Philadelphia, PA 19104, USA
    Cancer Lett 360:205-12. 2015
    ..We conclude that this SN38-TS NP formulation improved delivery, retention, and efficacy, without causing systemic toxicity. ..
  17. ncbi Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number
    Qun Wang
    Division of Oncology, Children s Hospital of Philadelphia, PA 19104 4399, USA
    Cancer Res 66:6050-62. 2006
    ..Lead positional candidates for neuroblastoma suppressor genes can be inferred from these data, but the potential multiplicity of transcripts involved has significant implications for ongoing gene discovery strategies...
  18. ncbi Evidence for a hereditary neuroblastoma predisposition locus at chromosome 16p12-13
    John M Maris
    Department of Pediatrics, University of Pennsylvania School of Medicine and Children s Hospital of Philadelphia, Abramson Pediatric Research Center, Philadelphia, Pennsylvania 19104 4318, USA
    Cancer Res 62:6651-8. 2002
    ..Taken together, these data suggest that a hereditary neuroblastoma predisposition gene (HNB1) is located at 16p12-13 and that disruption of this gene may contribute to the pathogenesis of nonfamilial neuroblastomas...
  19. ncbi Proliferation of human neuroblastomas mediated by the epidermal growth factor receptor
    Ruth Ho
    Division of Oncology, Children s Hospital of Philadelphia and University of Pennsylvania, Philadelphia, Pennsylvania 19104 4318, USA
    Cancer Res 65:9868-75. 2005
    ..Our results also indicate that ZD1839 is a potent inhibitor of neuroblastoma cell proliferation; therefore, it may be a useful, biologically based therapeutic agent for these tumors...
  20. ncbi CHD5, a new member of the chromodomain gene family, is preferentially expressed in the nervous system
    Patricia M Thompson
    Division of Oncology, The Children s Hospital of Philadelphia, Philadelphia, PA 19104, USA
    Oncogene 22:1002-11. 2003
    ..These findings suggest that this gene may play a role in the development of the nervous system, and it may also play a role in the pathogenesis of neural tumors...
  21. pmc Phase I trial of lestaurtinib for children with refractory neuroblastoma: a new approaches to neuroblastoma therapy consortium study
    Jane E Minturn
    Department of Pediatrics and Center for Childhood Cancer Research, Children s Hospital of Philadelphia, University of Pennsylvania, Philadelphia, PA, USA
    Cancer Chemother Pharmacol 68:1057-65. 2011
    ..TrkB acts as an oncogenic kinase in a subset of human neuroblastomas. Lestaurtinib, a multi-kinase inhibitor with potent activity against Trk kinases, has demonstrated activity in preclinical models of neuroblastoma...
  22. pmc Preclinical evaluation of lestaurtinib (CEP-701) in combination with retinoids for neuroblastoma
    Robin E Norris
    Division of Oncology, The Children s Hospital of Philadelphia, Philadelphia, PA 19104, USA
    Cancer Chemother Pharmacol 68:1469-75. 2011
    ..We studied the interaction of CEP-701 with isotretinoin (13cRA) and fenretinide (4HPR), two retinoids that have been studied in children with high-risk neuroblastoma...
  23. pmc Entrectinib is a potent inhibitor of Trk-driven neuroblastomas in a xenograft mouse model
    Radhika Iyer
    Division of Oncology, The Children s Hospital of Philadelphia, Philadelphia, PA 19104, USA
    Cancer Lett 372:179-86. 2016
    ..Our data suggest that entrectinib is a potent Trk inhibitor and should be tested in clinical trials for NBs and other Trk-expressing tumors...
  24. pmc Nanoparticle-mediated delivery of a rapidly activatable prodrug of SN-38 for neuroblastoma therapy
    Ivan S Alferiev
    Department of Pediatrics, The Children s Hospital of Philadelphia, Philadelphia, PA, 19104, USA
    Biomaterials 51:22-9. 2015
    ....
  25. pmc Therapeutic targets for neuroblastomas
    Garrett M Brodeur
    Children s Hospital of Philadelphia, Division of Oncology, CTRB Rm 3018, 3501 Civic Center Blvd, Philadelphia, PA 19104 4302, USA 1 215 590 2817 1 215 590 3770
    Expert Opin Ther Targets 18:277-92. 2014
    ..Further, there is considerable short- and long-term toxicity. More effective, less toxic therapy is needed, and the development of targeted therapies offers great promise...
  26. ncbi Significance of intratumoral genetic heterogeneity in neuroblastomas
    Garrett M Brodeur
    Division of Oncology, The Children s Hospital of Philadelphia, Abramson Research Center, Philadelphia, Pennsylvania 19104 4318, USA
    Med Pediatr Oncol 38:112-3. 2002
  27. pmc The tumour suppressor CHD5 forms a NuRD-type chromatin remodelling complex
    Venkatadri Kolla
    Division of Oncology, Department of Pediatrics, The Children s Hospital of Philadelphia, University of Pennsylvania, Philadelphia 19104, PA, U S A
    Biochem J 468:345-52. 2015
    ..However, CHD5-NuRD may also have unique protein associations that confer functional specificity and may contribute to normal development and to tumour suppression in NB and other cancers. ..
  28. ncbi Expression of the neurotrophin receptor TrkA down-regulates expression and function of angiogenic stimulators in SH-SY5Y neuroblastoma cells
    Angelika Eggert
    Division of Oncology, The Children s Hospital of Philadelphia and Department of Pediatrics, The University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Cancer Res 62:1802-8. 2002
    ..The biologically different behavior of TrkA- and TrkB-expressing NBs may be explained in part by their effects on angiogenesis...
  29. pmc CHD5 is required for spermiogenesis and chromatin condensation
    Tiangang Zhuang
    Division of Oncology, The Children s Hospital of Philadelphia, Philadelphia, PA 19104, United States
    Mech Dev 131:35-46. 2014
    ..Our data indicate that CHD5 is required for normal spermiogenesis, especially for spermatid chromatin condensation. ..
  30. pmc TrkB inhibition by GNF-4256 slows growth and enhances chemotherapeutic efficacy in neuroblastoma xenografts
    Jamie L Croucher
    Oncology Research, The Children s Hospital of Philadelphia, CTRB Rm 3018, 3501 Civic Center Blvd, Philadelphia, PA, 19104 4302, USA
    Cancer Chemother Pharmacol 75:131-41. 2015
    ..Indeed, TrkB and its ligand, brain-derived neurotrophic factor (BDNF), are expressed in 50-60 % of high-risk NBs. The BDNF/TrkB autocrine pathway enhances survival, invasion, metastasis, angiogenesis and drug resistance...
  31. ncbi Genomic annotation of the meningioma tumor suppressor locus on chromosome 1p34
    Erik P Sulman
    The Fels Institute for Molecular Biology and Cancer Research, Temple University School of Medicine, Philadelphia, PA 19140, USA
    Oncogene 23:1014-20. 2004
    ..This annotation of a putative tumor suppressor locus provides a resource for further analysis of meningioma candidate genes...
  32. doi Management of adrenal masses in patients with Beckwith-Wiedemann syndrome
    Suzanne P MacFarland
    Division of Oncology, The Children s Hospital of Philadelphia, Philadelphia, Pennsylvania
    Pediatr Blood Cancer . 2017
    ....
  33. ncbi No evidence for the presence of an imprinted neuroblastoma suppressor gene within chromosome sub-band 1p36.3
    Michael D Hogarty
    Division of Oncology, The Children s Hospital of Philadelphia, Philadelphia, Pennsylvania 19104 4318, USA
    Cancer Res 62:6481-4. 2002
    ..58). These data strongly refute a parent-of-origin effect for 1p deletions in NB and exclude the existence of an imprinted NB suppressor locus in this region...
  34. pmc Rotary bioreactor culture can discern specific behavior phenotypes in Trk-null and Trk-expressing neuroblastoma cell lines
    Robert A Redden
    Department of General, Thoracic, and Fetal Surgery, The Children s Hospital of Philadelphia, 34th and Civic Center Blvd Wood Center, 5th Floor, Philadelphia, PA, 19104, USA
    In Vitro Cell Dev Biol Anim 50:188-93. 2014
    ..The microgravity bioreactor is a useful in vitro tool to rapidly investigate the biological characteristics of neuroblastoma and potentially to assess the effect of cytotoxic as well as biologically targeted drugs...